vs

Side-by-side financial comparison of Ategrity Specialty Insurance Co Holdings (ASIC) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $116.1M, roughly 1.9× Ategrity Specialty Insurance Co Holdings). Ategrity Specialty Insurance Co Holdings runs the higher net margin — 19.5% vs 19.4%, a 0.2% gap on every dollar of revenue.

Ategrity Specialty Insurance Co Holdings is a specialty insurance holding company that provides commercial property and casualty insurance solutions. It primarily focuses on excess and surplus lines coverage, serving niche segments including construction, healthcare, and small business markets across the United States, offering tailored policies for unique, hard-to-place risks that standard carriers do not typically cover.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

ASIC vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.9× larger
ORGO
$225.6M
$116.1M
ASIC
Higher net margin
ASIC
ASIC
0.2% more per $
ASIC
19.5%
19.4%
ORGO

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ASIC
ASIC
ORGO
ORGO
Revenue
$116.1M
$225.6M
Net Profit
$22.7M
$43.7M
Gross Margin
Operating Margin
25.6%
28.1%
Net Margin
19.5%
19.4%
Revenue YoY
78.1%
Net Profit YoY
469.5%
EPS (diluted)
$0.45
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASIC
ASIC
ORGO
ORGO
Q4 25
$225.6M
Q3 25
$116.1M
$150.9M
Q2 25
$101.8M
$101.0M
Q1 25
$86.7M
Q4 24
$126.7M
Q3 24
$115.2M
Q2 24
$130.2M
Q1 24
$110.0M
Net Profit
ASIC
ASIC
ORGO
ORGO
Q4 25
$43.7M
Q3 25
$22.7M
$21.6M
Q2 25
$17.6M
$-9.4M
Q1 25
$-18.8M
Q4 24
$7.7M
Q3 24
$12.3M
Q2 24
$-17.0M
Q1 24
$-2.1M
Gross Margin
ASIC
ASIC
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Q1 24
73.9%
Operating Margin
ASIC
ASIC
ORGO
ORGO
Q4 25
28.1%
Q3 25
25.6%
13.7%
Q2 25
21.9%
-12.5%
Q1 25
-30.9%
Q4 24
8.1%
Q3 24
5.4%
Q2 24
-10.7%
Q1 24
-3.5%
Net Margin
ASIC
ASIC
ORGO
ORGO
Q4 25
19.4%
Q3 25
19.5%
14.3%
Q2 25
17.3%
-9.3%
Q1 25
-21.7%
Q4 24
6.1%
Q3 24
10.7%
Q2 24
-13.1%
Q1 24
-1.9%
EPS (diluted)
ASIC
ASIC
ORGO
ORGO
Q4 25
$0.31
Q3 25
$0.45
$0.11
Q2 25
$0.39
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$0.09
Q2 24
$-0.13
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASIC
ASIC
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$34.3M
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$588.6M
$300.1M
Total Assets
$1.4B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASIC
ASIC
ORGO
ORGO
Q4 25
$93.7M
Q3 25
$34.3M
$63.7M
Q2 25
$23.5M
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Q1 24
$88.6M
Total Debt
ASIC
ASIC
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
ASIC
ASIC
ORGO
ORGO
Q4 25
$300.1M
Q3 25
$588.6M
$255.1M
Q2 25
$559.7M
$233.2M
Q1 25
$242.9M
Q4 24
$262.9M
Q3 24
$278.5M
Q2 24
$263.5M
Q1 24
$278.0M
Total Assets
ASIC
ASIC
ORGO
ORGO
Q4 25
$598.7M
Q3 25
$1.4B
$509.8M
Q2 25
$1.4B
$461.1M
Q1 25
$467.4M
Q4 24
$497.9M
Q3 24
$446.3M
Q2 24
$443.2M
Q1 24
$458.5M
Debt / Equity
ASIC
ASIC
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASIC
ASIC
ORGO
ORGO
Operating Cash FlowLast quarter
$41.1M
$39.4M
Free Cash FlowOCF − Capex
$34.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
2.1%
Cash ConversionOCF / Net Profit
1.81×
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASIC
ASIC
ORGO
ORGO
Q4 25
$39.4M
Q3 25
$41.1M
$3.1M
Q2 25
$50.8M
$-32.9M
Q1 25
$-19.9M
Q4 24
$10.9M
Q3 24
$8.7M
Q2 24
$4.7M
Q1 24
$-10.2M
Free Cash Flow
ASIC
ASIC
ORGO
ORGO
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
Q1 24
$-12.4M
FCF Margin
ASIC
ASIC
ORGO
ORGO
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Q1 24
-11.3%
Capex Intensity
ASIC
ASIC
ORGO
ORGO
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Q1 24
2.0%
Cash Conversion
ASIC
ASIC
ORGO
ORGO
Q4 25
0.90×
Q3 25
1.81×
0.14×
Q2 25
2.88×
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons